AstraZeneca And Pfizer Call For Measures To Avoid Mix-up Between Nolvadex And Norvasc In Japan
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca, seller of cancer therapy Nolvadex (tamoxifen) and Pfizer, seller of hypertension therapy Norvasc (amlodipine) have published a document in Japan urging institutions to avoid mix-up of the two drugs, which in the Japanese language have similar pronunciations and spellings.